AVEO Oncology (AVEO -11.7%) is under pressure, although up from the intraday low of $7.05, on the heels of its report of overall survival (OS) data from its Phase 3 TIVO-3 study comparing tivozanib to Bayer’s (OTCPK:BAYRY -0.6%) Nexavar (sorafenib) in renal cell carcinoma patients in third- and fourth-line settings.
As previously announced, the trial met the primary
endpoint of progression-free survival (PFS) and the secondary endpoint
of overall response rate (ORR) with 3% less risk of cancer progression
or death.
Tivozanib fell short of sorafenib in median OS, 16.4 months versus 19.2 months, however.
#ASCO20
https://seekingalpha.com/news/3578686-aveo-down-12-on-tivozanib-survival-data-in-kidney-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.